版权说明 操作指南
首页 > 成果 > 详情

CXC chemokine ligand 12 (CXCL12) in atherosclerosis: An underlying therapeutic target

认领
导出
下载 Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Gao, Jia-Hui;Yu, Xiao-Hua;Tang, Chao-Ke*
通讯作者:
Tang, Chao-Ke
作者机构:
[Tang, Chao-Ke; Yu, Xiao-Hua; Gao, Jia-Hui] Univ South China, Inst Cardiovasc Dis, Key Lab Atherosclerol Hunan Prov, Med Res Expt Ctr,Hunan Prov Cooperat Innovat Ctr, Hengyang 421001, Hunan, Peoples R China.
[Tang, Chao-Ke] Univ South China, Inst Cardiovasc Res, Hengyang 421001, Hunan, Peoples R China.
通讯机构:
[Tang, Chao-Ke] U
Univ South China, Inst Cardiovasc Res, Hengyang 421001, Hunan, Peoples R China.
语种:
英文
关键词:
Atherosclerosis;CXCL12;CXCR4;CXCR7
期刊:
Clinica Chimica Acta
ISSN:
0009-8981
年:
2019
卷:
495
页码:
538-544
基金类别:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81770461]
机构署名:
本校为第一且通讯机构
院系归属:
医学院
摘要:
CXC chemokine ligand 12 (CXCL12) is a specific chemokine ligand and plays a significant role in cell chemotaxis. Upon binding to CXC chemokine receptor 4 (CXCR4) or CXCR7, CXCL12 can activate different signaling cascades to regulate cell proliferation, migration, and metabolism. CXCL12 exerts a pro-atherogenic action by aggravating multiple pathogenesis of atherogenesis, including dyslipidemia, inflammation, neointima hyperplasia, angiogenesis, and insulin resistance. Serum CXCL12 levels are also markedly increased in patients with atherosclerosis-associated disease. The present review focuses...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com